Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsSelectHealth pharmacy prior auth policy update | O…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentSelectHealthPolicy N/A

    Actimmune (interferon gamma-1b) — Coverage and Prior Authorization Criteria

    Customize your policy alerts

    Sign up for all SelectHealth policy alerts

    Know when SelectHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization requirements for Actimmune (interferon gamma-1b) for SelectHealth members, including required diagnoses and exclusions. Applies to medication benefit determinations for Plan Year authorizations.

    Policy Summary
    PayerSelectHealth
    PolicyActimmune (interferon gamma-1b) — Coverage and Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and document diagnosis of chronic granulomatous disease or severe malignant osteopetrosis with required supporting information.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1FDA-approved indications listed
    2Required diagnoses specified
    1Explicit exclusion (hypersensitivity)
    Plan YearCoverage duration
    >=2Required testosterone tests

    Coverage Criteria and Medication-Specific Initial Requirements

    Initial Therapy

    Covered when ALL of the following are met

    Actimmune coverage criteria: 1) Indication is an FDA-approved indication for Actimmune; 2) Member has a documented diagnosis of chronic granulomatous disease OR severe malignant osteopetrosis; 3) Coverage duration authorized for the Plan Year.

    See exclusions for hypersensitivity.

    Alecensa - Initial Coverage

    Covered when ALL of the following are met

    Alecensa initial coverage: 1. Medication: ALECENSA; 2. PA indication indicator: All FDA‑Approved Indications; 3. Required medical information: Diagnosis of non‑small cell lung cancer that is ALK‑positive with tumors confirmed ALK‑positive; 4. Coverage duration: Plan Year.

    From chunks 20,21,24,27

    Radicava ORS - Initial Coverage

    Policy Summary
    PayerSelectHealth
    PolicyActimmune (interferon gamma-1b) — Coverage and Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and document diagnosis of chronic granulomatous disease or severe malignant osteopetrosis with required supporting information.
    SourceLink
    On This Page
    Coverage Criteria and Medication-Specific Initial RequirementsPrior Authorization, Documentation and Denial RisksInitial Therapy Criteria (Per-Drug Blocks)Reauthorization and Continuation RequirementsStep Therapy Rules and Prior Trial RequirementsMedication and Clinical Codes, Key ValuesDefinitions and Diagnostic CriteriaSite of Care RequirementsBackground and Scope

    Covered when ALL of the following are met

    Radicava ORS initial coverage: 1. Medication: RADICAVA ORS or RADICAVA ORS STARTER KIT; 2. PA indication indicator: All FDA‑Approved Indications; 3. Required medical information: Diagnosis of amyotrophic lateral sclerosis (ALS) as defined by the revised El Escorial criteria; 4. Coverage duration: Plan Year.

    From chunks 30,31,34,37

    ALUNBRIG Initial Therapy

    ALUNBRIG (partial criteria in this segment): Covered when ALL of the following are met

    ALUNBRIG initial coverage: 1) Diagnosis of metastatic non‑small cell lung cancer (NSCLC) with tumors that are ALK‑positive; 2) Patient has failed, is intolerant to, or has a contraindication to Alecensa;

    Coverage duration: Plan Year

    Testosterone Initial Therapy

    Testosterone topical/solution (partial criteria in this segment): Covered when ALL of the following are met

    Testosterone initial coverage: 1) Two separate testosterone levels drawn on different dates with serum testosterone < 300 ng/dL; 2) Patient experiences at least ONE qualifying symptom (malaise, fatigue, lethargy, muscle loss, depression, decreased libido);serum testosterone < 300 ng/dL

    Coverage duration: Plan Year

    Required Medical Information — Testosterone

    Covered when ALL of the following are met

    Testosterone criteria: 1) Two separate testosterone levels drawn on different dates where the serum testosterone level is below 300 ng/dL; 2) Patient experiences at least ONE of: malaise, fatigue, lethargy, muscle loss, depression, decreased libido.serum testosterone < 300 ng/dL

    From Required Medical Information

    Required Medical Information — Antipsychotics / Rexulti

    Covered when ALL of the following prior trials documented

    Antipsychotic prior trials: Previous trial on one or more of: aripiprazole, clozapine, fluoxetine‑olanzapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone; and for Major Depressive Disorder or Schizophrenia: previous trial on Rexulti.prior trials documented

    From Required Medical Information

    Initial coverage for extreme LDL elevations

    Covered when ALL of the following are met

    LDL criteria: 1. Untreated fasting LDL > 500 mg/dL AND triglycerides < 300 mg/dL; 2. Patient meets (a OR b) AND c where: a) documented mutations in both alleles of the LDL receptor or other genes affecting LDL receptor function; b) both parents have history of untreated total cholesterol >250 mg/dL; c) presence of xanthomas before age 10; 3. Patient has failed or is currently taking at least ONE of: a) Atorvastatin, Rosuvastatin, or Simvastatin; b) documented intolerance to statin therapy (e.g., rhabdomyolysis); 4. Patient has previous trial of Repatha OR Praluent.

    AQNEURSA initial therapy criteria

    Covered when ALL of the following are met

    NPC criteria: 1. Prior ≥3 months miglustat therapy without improvement in disease progression; 2. Patient weight ≥ 15 kg; 3. Diagnosis genetically confirmed by biallelic NPC1 or NPC2 mutations OR if only one allele mutated then positive filipin staining or elevated cholestane triol oxysterols (>2x ULN); 4. Patient presents with at least one neurologic symptom (examples: hearing loss, vertical supranuclear gaze palsy, ataxia, dementia, dystonia, seizures, dysarthria, dysphagia); 5. Patient is able to walk independently or with assistance; 6. AND one of: A) Gait subtest of SARA within 2–7 (on 0–8 scale) OR B) 9‑Hole Peg Test dominant hand between 20 and 150 seconds.

    AQNEURSA reauthorization

    Reauthorization covered when

    AQNEURSA reauthorization: SARA score has remained stable or improved.

    Arcalyst — Initial Coverage

    Covered when ALL of the following are met

    Arcalyst initial: 1) Indication is one of: cryopyrin‑associated periodic syndrome, recurrent pericarditis, or DIRA; 2) Not used in combination with a TNF‑inhibitor; 3) Prior authorization requested for an FDA‑approved indication; 4) Coverage duration: Plan Year.

    Adbry — Initial and Reauthorization

    Covered when ALL of the following are met

    Adbry initial: 1) Diagnosis of moderate to severe atopic dermatitis with ≥10% body surface area involvement; 2) Failure of two of: topical corticosteroid, topical calcineurin inhibitor, phototherapy, oral immunomodulator (azathioprine, cyclosporine, mycophenolate), or topical PDE‑4; 3) Prior authorization requested for an FDA‑approved indication; 4) Coverage duration: Plan Year.

    For reauthorization: for patients <100 kg who achieved clear or almost clear skin, an every‑4‑week dosing trial must have been tried.

    AUGTYRO - Initial Coverage

    AUGTYRO (Part B) is covered when ALL of the following are met:

    AUGTYRO coverage criteria: 1) Diagnosis of locally advanced or metastatic ROS1‑positive NSCLC OR NTRK gene fusion‑positive solid tumors; 2) Documentation of contraindication, intolerance, or failure of Rozlytrek; 3) Prior authorization for an FDA‑approved indication; 4) Coverage duration: Plan Year.

    AUSTEDO - Initial Coverage

    AUSTEDO / AUSTEDO XR (Part B) is covered when ALL of the following are met:

    AUSTEDO coverage criteria: 1) Diagnosis of chorea associated with Huntington's disease OR diagnosis of tardive dyskinesia; 2) Prior authorization for an FDA‑approved indication; 3) Coverage duration: Plan Year.

    Initial therapy — recurrent low-grade serous ovarian cancer

    Covered when ALL of the following are met for the recurrent KRAS‑mutated low‑grade serous ovarian cancer indication

    Recurrent KRAS‑mutated low‑grade serous ovarian cancer: Diagnosis of recurrent KRAS‑mutated, recurrent low‑grade serous ovarian cancer.
    Prior platinum therapy: Prior therapy including platinum‑based therapy.
    ECOG performance: Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
    Prior Mekinist: Patient has been treated with Mekinist or documented medical rationale has been provided explaining why it would be inappropriate treatment for the patient.

    Reauthorization — no progression required

    Reauthorization requires ALL of the following

    No progression: Documentation showing patient does not have disease progression (defined as >=20% increase in sum of diameters of target lesions per RECIST v1.1)>=20%

    AYVAKIT indications

    Covered when diagnosis matches one of the listed FDA‑approved indications

    GIST PDGFRA exon 18: Unresectable or metastatic GIST that is PDGFRA exon 18 mutation positive including PDGFRA D842V mutations.
    Advanced Systemic Mastocytosis (ASM), including ASM, SM‑AHN, and mast cell leukemia (MCL).
    Indolent Systemic Mastocytosis.

    Balversa — Initial Therapy

    Covered when ALL of the following are met

    Balversa initial: 1) Diagnosis of locally advanced or metastatic urothelial carcinoma; 2) Confirmed FGFR3 genetic alteration; 3) Progression on or after at least one line of prior systemic therapy; 4) Coverage duration: Plan Year.

    Rufinamide — Initial Therapy

    Covered when ALL of the following are met

    Rufinamide initial: 1) Patient has inadequate seizure control despite treatment with at least one anti‑epileptic drug; 2) Coverage duration: Plan Year.

    Seizure-related coverage

    Covered when ALL of the following are met

    Seizure indication: Patient has inadequate seizure control despite treatment with at least ONE anti‑epileptic drug.>=1 AED

    Coverage duration: Plan Year

    Lupus nephritis / SLE coverage

    Covered when ALL of the following are met

    Lupus nephritis/SLE indication: Diagnosis of lupus nephritis or systemic lupus erythematosus; current active disease; previous treatment with at least TWO of corticosteroids, antimalarials, or immunosuppressives; patient will continue concomitant standard treatment with at least ONE of corticosteroids, antimalarials, or immunosuppressives.>=2 prior therapies

    Coverage duration: Plan Year

    Initial Therapy (Polycythemia Vera)

    Covered when ALL of the following are met

    Polycythemia Vera indications: 1. Diagnosis of Polycythemia Vera; 2. Inadequate response or intolerance to hydroxyurea.

    Initial coverage duration: 6 months; reauthorization: Plan Year

    Initial Therapy (Ph+ CML)

    Covered when ALL of the following are met

    Ph+ CML indications: 1. Patient diagnosed with Philadelphia chromosome positive (Ph+) CML with phase specified; 2. For chronic phase CML, previous failure or intolerance to imatinib is required.

    Coverage duration: Plan Year

    Initial therapy — BRAFTOVI/MEKTOVI

    BRAFTOVI (encorafenib) with MEKTOVI (binimetinib) — covered when ALL of the following are met

    BRAF‑mutant indication: Diagnosis of BRAF V600E or V600K mutation‑positive unresectable or metastatic melanoma; OR BRAF V600E mutation‑positive metastatic colorectal cancer when encorafenib will be combined with cetuximab; OR BRAF V600E mutation‑positive metastatic NSCLC when used with encorafenib and binimetinib.

    Molecular testing documentation required

    Combination therapy: Will be used as combination therapy with encorafenib [Braftovi] and binimetinib [Mektovi] for melanoma or NSCLC; for metastatic colorectal cancer indicates encorafenib will be combined with cetuximab.

    Treatment combination must be documented

    Initial therapy — BRUKINSA

    BRUKINSA (zanubrutinib) — covered when ALL of the following are met

    Diagnosis: Documented diagnosis of one of: mantle cell lymphoma (MCL); Waldenström macroglobulinemia; relapsed or refractory follicular lymphoma (FL); chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

    Specific diagnosis must be documented

    Prior therapy requirements: Documentation of prior therapies as applicable: at least one prior therapy for MCL; prior anti‑CD20–based regimen for MZL; two or more lines of therapy for FL when used in combination with obinutuzumab; prior treatment history for other listed diagnoses as applicable.

    Prior therapy lines must be documented

    CABLIVI: Initial and Reauthorization

    Covered when ALL of the following are met

    CABLIVI initial authorization: Diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP); started inpatient in combination with plasma exchange.

    Initial authorization requirement

    CABLIVI reauthorization: Evidence of persistent underlying disease (e.g., suppressed ADAMTS13 concentrations) AND demonstrated positive response to therapy by clinically significant increase in platelet count OR reduction in neurological symptoms OR improvement in organ‑damage markers.

    Reauthorization requires disease persistence plus clinical response

    CABLIVI duration limits: Coverage duration 3 months; maximum duration of 58 days following last day of plasma exchange.

    Duration constraints

    CABOMETYX: Indication and prior therapy requirements

    Covered for ALL FDA‑approved indications when documentation of the specific indication and prior therapy requirements are provided

    Hepatocellular carcinoma (HCC): Diagnosis of hepatocellular carcinoma with previous use of sorafenib.

    Per document: prior sorafenib required

    Advanced renal cell carcinoma (RCC): Diagnosis of advanced renal cell carcinoma.
    Differentiated thyroid cancer (DTC): Diagnosis of locally advanced or metastatic DTC with progression following prior VEGFR‑targeted therapy AND patient is radioactive iodine‑refractory or ineligible.
    Previously treated pNET: Unresectable, locally advanced or metastatic, well‑differentiated pancreatic neuroendocrine tumors with prior failure of everolimus or sunitinib.
    Previously treated extra‑pancreatic NET (epNET): Previously treated, unresectable, locally advanced or metastatic, well‑differentiated extra‑pancreatic neuroendocrine tumors.

    CALQUENCE (acalabrutinib) - Initial Therapy

    Covered when ALL of the following are met

    CALQUENCE initial coverage: Medication: CALQUENCE 100 mg tab; Diagnosis: mantle cell lymphoma; Patient has been treated with at least one prior therapy; Indication matches an FDA‑approved indication; Coverage duration: Plan Year.

    CAPRELSA (vandetanib) - Initial Therapy

    Covered when ALL of the following are met

    CAPRELSA initial coverage: Medication: CAPRELSA; Diagnosis: symptomatic or progressive medullary thyroid cancer that is unresectable locally advanced or metastatic; Indication matches an FDA‑approved indication; Coverage duration: Plan Year.

    Extracted coverage criteria (partial)

    Coverage and required information for specific medications in this fragment:

    Medullary thyroid cancer indication: Diagnosis: symptomatic or progressive medullary thyroid cancer with unresectable locally advanced or metastatic disease.

    Covered when this diagnosis is documented

    Carglumic acid: Required medical information: hyperammonemia due to N‑acetylglutamate synthase deficiency.

    PA indicator: All FDA‑Approved Indications; Coverage duration: Plan Year

    Sapropterin: Required medical information: hyperphenylalaninemia due to BH4‑responsive phenylketonuria.

    PA indicator: All FDA‑Approved Indications; Coverage duration: Plan Year

    Cholbam: Listed as a medication with PA indicator: All FDA‑Approved Indications.

    No additional required medical information in this fragment

    Coverage is excluded for members with a documented hypersensitivity to Actimmune or to E. coli–derived products. This exclusion should be confirmed during prior authorization review and recorded in the member's chart; requests meeting this exclusion should be denied.

    For the segments summarized here there are no specific off‑label uses, exclusion criteria, age restrictions, or prescriber restrictions documented (listed as NIA in the source). When a field is marked NIA, the policy provides no additional limits in that category for the listed medication in these chunks.

    No explicit exclusion criteria are provided in these sections of the policy (entries shown as NIA). Reviewers should rely on medication‑specific contraindications elsewhere in the record if present.

    For JUXTAPID the policy lists a history of significant hepatic disease or alcohol abuse as exclusion criteria. Presence of either condition is an exclusion that may lead to denial of coverage.

    The policy indicates exclusion for patients with significant hepatic disease or alcohol abuse. In addition, use of the medication in combination with Miplyffa is listed as an exclusion. Requests documenting these conditions or combination use should be denied.

    Combination therapy with a TNF‑inhibitor is specifically listed as an exclusion for Arcalyst. Prior authorization requests proposing concurrent TNF‑inhibitor therapy should be declined.

    These segments report NIA (no information available/not indicated) for off‑label uses, exclusion criteria, and other criteria. No additional exclusionary rules are specified in this portion of the policy.

    No explicit exclusion criteria are listed in these chunks (entries marked NIA). Absent specific exclusions here, apply medication‑specific contraindications from other policy sections or product labeling as appropriate.

    This portion of the policy lists NIA across off‑label uses, age restriction, prescriber restriction and exclusion criteria fields, indicating no explicit restrictions were provided in the extract.

    The entries in these segments indicate NIA under Exclusion Criteria. No exclusionary conditions are specified here in the source fragments.

    Multiple entries in this section are marked NIA for off‑label uses, exclusion criteria, age and prescriber restrictions, and other criteria. The policy provides no additional exclusionary language in these chunks.

    These segments explicitly state that off‑label uses are not applicable or not available (NIA) for the listed medications. No off‑label coverage is described here.

    This extract lists multiple NIA entries for off‑label uses, exclusion criteria, age restriction, prescriber restriction, and Part B prerequisites. No specific exclusions or restrictions are provided in these chunks.

    No off‑label uses, age or prescriber restrictions, other criteria, or exclusion criteria are specified in this fragment (marked NIA).

    This fragment is marked NIA for exclusion criteria and provides no specific exclusionary rules. If supporting documentation is lacking elsewhere, standard denial triggers may still apply.

    Off‑label uses are marked NIA for the medications referenced in these segments. The policy does not identify any off‑label indications in this portion of the document.

    Off‑label use entries in these chunks are indicated as NIA (not available/not indicated). No off‑label coverage criteria are provided here.

    Prior Authorization, Documentation and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for all FDA‑approved indications of covered medications listed in this policy. Providers must document the specific diagnosis that aligns with the requested FDA indication. Coverage is limited to FDA‑approved uses and non‑FDA uses may be denied.

    • PA required: All FDA‑Approved Indications
    • Provider must document diagnosis that matches the FDA indication
    Denial Risk

    Exclusions That May Trigger Denial

    Exclusion: Do not approve therapy for patients with known hypersensitivity to Actimmune or other E. coli–derived products. Combination use with a TNF‑inhibitor (where noted for specific agents) is excluded and may lead to denial.

    • Exclusion: Hypersensitivity to Actimmune or E. coli‑derived products
    • Exclusion: Combination use with TNF‑inhibitor (where specified)
    Documentation Required

    Alecensa — Documentation Requirements and Risk

    Alecensa requests must include documentation of ALK‑positive NSCLC. Lack of documentation confirming ALK‑positive tumor status or absence of required diagnostic information may result in denial.

    • Required: Dx of NSCLC that is ALK‑positive; tumor ALK status documented
    • Denial risk if ALK‑positive documentation is missing
    Documentation Required

    Radicava ORS — Required Documentation

    Radicava ORS (edaravone) requests must include documentation that the patient meets revised El Escorial criteria for ALS. Failure to provide El Escorial criteria documentation may result in denial.

    • Required: Diagnosis of ALS as defined by the revised El Escorial criteria
    • Denial risk if El Escorial documentation is missing
    Documentation Required

    Testosterone — Required Testing and Symptom Documentation

    Testosterone therapy requires two separate testosterone measurements (drawn on different dates) with serum testosterone < 300 ng/dL and documentation of at least one clinical symptom (for example: malaise, fatigue, lethargy, muscle loss, depression, decreased libido). Requests missing the two test results or symptom documentation may be denied.

    • Two separate testosterone levels, on different dates, both < 300 ng/dL
    • Document at least one symptom: malaise, fatigue, lethargy, muscle loss, depression, decreased libido
    • Denial risk if required testing or symptom documentation absent
    Step Therapy

    Prior Trial Documentation — Antipsychotics and Rexulti

    For antipsychotic therapies where prior trials are required, document trials of relevant agents (for example: aripiprazole, clozapine, fluoxetine‑olanzapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone). Where Rexulti is indicated for MDD or schizophrenia, document a previous trial of Rexulti when specified.

    • Document prior trials of listed antipsychotics as applicable
    • For MDD or Schizophrenia indications: document previous trial on Rexulti when required
    Documentation Required

    LDL‑Related Indication — Required Documentation and Prior Therapy

    For the LDL‑related (homozygous familial hypercholesterolemia) indication, document untreated fasting LDL > 500 mg/dL and triglycerides < 300 mg/dL. Provide genetic/family history evidence (biallelic LDL receptor mutations OR both parents with untreated total cholesterol > 250 mg/dL OR xanthomas before age 10). Document prior trials of high‑intensity statin therapy and intolerance if applicable, and prior trial of PCSK9 inhibitor (Repatha or Praluent).

    • Untreated fasting LDL > 500 mg/dL AND triglycerides < 300 mg/dL
    • Genetic/family history: biallelic LDL receptor mutation OR parental hypercholesterolemia OR childhood xanthomas
    • Document prior high‑intensity statin trial or documented statin intolerance
    • Document prior trial of Repatha OR Praluent
    Prior Authorization

    AUGTYRO — PA Indication and Required Documentation

    AUGTYRO (entrectinib/indication context) requests must include diagnosis of locally advanced or metastatic ROS1‑positive NSCLC or NTRK gene fusion–positive solid tumor and documentation of contraindication, intolerance, or failure of Rozlytrek when required by indication. Missing ROS1/NTRK or prior‑therapy rationale may trigger denial.

    • Required: Dx of ROS1‑positive NSCLC or NTRK gene fusion‑positive solid tumor
    • Document contraindication/intolerance/failure of Rozlytrek when applicable
    • Denial risk if ROS1/NTRK or prior therapy rationale missing
    Prior Authorization

    AUSTEDO — PA Indication and Documentation

    AUSTEDO (deutetrabenazine) requests must document the specific diagnosis: chorea associated with Huntington's disease OR tardive dyskinesia. Lack of a documented diagnosis for chorea or TD may result in denial.

    • Required: Dx of chorea associated with Huntington's disease OR Dx of tardive dyskinesia
    • Denial risk if required diagnosis is not provided
    Prior Authorization

    Medication‑Specific PA and Documentation Expectations

    Medication‑specific prior authorization notes: include diagnosis, relevant mutation status or laboratory results, prior therapy trials or intolerances, and any indication‑specific exclusions. Failure to supply required medical information for the specific drug/indication may lead to denial.

    • Include diagnosis, labs/genetic test results, prior therapies/intolerances as applicable
    • Missing required medical information for a specific medication/indication may cause denial
    Prior Authorization

    CABLIVI — Prior Authorization and Reauthorization Requirements

    CABLIVI (caplacizumab) initial authorization requires a diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP) AND that therapy was started inpatient in combination with plasma exchange. Reauthorization requires evidence of persistent underlying disease (for example suppressed ADAMTS13) and clinical response (increased platelet count, reduced neurologic symptoms, or improved organ‑damage markers). Max duration: 58 days following the last day of plasma exchange. Initial coverage duration: 3 months.

    • Initial: Dx of aTTP AND inpatient start with plasma exchange
    • Reauthorization: evidence of persistent underlying disease and demonstrated clinical response
    • Max duration: 58 days following last plasma exchange
    • Coverage duration (initial): 3 months
    Prior Authorization

    CABOMETYX — Required Diagnosis and Prior Therapy Documentation

    CABOMETYX (cabozantinib) requests must document the specific indicated diagnosis (hepatocellular carcinoma with prior sorafenib use; advanced renal cell carcinoma; locally advanced/metastatic differentiated thyroid cancer with progression after VEGFR‑targeted therapy or radioactive iodine‑refractory; previously treated unresectable/metastatic well‑differentiated pNET with prior everolimus or sunitinib; or extra‑pancreatic NET). Provide prior therapy details (e.g., previous sorafenib for HCC) as applicable. Missing the specified diagnosis or prior‑therapy documentation may lead to denial.

    • Document indicated diagnosis and prior therapies (e.g., prior sorafenib for HCC)
    • Indication‑specific prior therapy requirements must be shown
    • Denial risk if diagnosis or prior therapy documentation is missing
    Documentation Required

    BRAFTOVI/MEKTOVI — Mutation Confirmation Required

    BRAFTOVI (encorafenib) used with Mektovi requires confirmation of BRAF V600E or V600K mutation for the indicated malignancy (melanoma, metastatic colorectal cancer when combined with cetuximab, or metastatic NSCLC). Lack of documented BRAF mutation status may result in denial.

    • Required: Documentation of BRAF V600E or V600K mutation for indicated uses
    • Specify planned combination therapy (encorafenib with binimetinib or with cetuximab) per indication
    • Denial risk if BRAF mutation confirmation missing
    Documentation Required

    Ph+ CML — Prior Therapy Requirement

    For Philadelphia chromosome‑positive (Ph+) CML indications, document the disease phase (chronic/accelerated/blast) and prior therapy history. For chronic phase (and other phases where indicated), prior failure or intolerance to imatinib must be documented before approval.

    • Required: Dx of Ph+ CML and documentation of disease phase
    • Document prior failure or intolerance to imatinib when required
    Documentation Required

    Balversa and Rufinamide — Required Diagnostic and Prior Therapy Information

    Balversa (erdafitinib) requires documentation of confirmed FGFR3 genetic alteration and progression on or after at least one line of prior systemic therapy. Rufinamide requests must show inadequate seizure control despite treatment with at least one anti‑epileptic drug.

    • Balversa: Confirmed FGFR3 alteration and prior systemic therapy documented
    • Rufinamide: Document inadequate seizure control despite ≥1 AED
    Prior Authorization

    Coverage Duration Requirements

    Some indications have defined coverage durations: typical coverage is Plan Year unless otherwise specified. Example: initial coverage for select indications (e.g., polycythemia vera entry) may be 6 months with reauthorization per Plan Year; CABLIVI initial authorization and limits are specified separately.

    • Default coverage duration: Plan Year
    • Example exception: Initial 6 months with reauthorization Plan Year for select entries (e.g., polycythemia vera)
    • CABLIVI: Initial coverage duration 3 months (max 58 days post plasma exchange)
    Step Therapy

    Prior Therapy or Rationale Required

    When a prior medication (e.g., Mekinist) is expected in the treatment sequence, either document prior use or provide a clinical rationale explaining why prior therapy would be inappropriate. Absence of prior therapy documentation or rationale may trigger denial.

    • Document prior Mekinist treatment or provide documented medical rationale for not using it
    • Missing prior therapy documentation or rationale may cause denial
    Note

    FDA Indication Alignment

    FDA‑indication alignment: Coverage is generally limited to FDA‑approved indications listed in this policy. Requests for uses outside FDA indications should include supporting clinical evidence; lack of FDA alignment or required supporting information may result in denial.

    • Coverage limited to FDA‑approved indications unless compelling supporting documentation provided
    • Non‑FDA uses subject to denial without adequate clinical justification

    Initial Therapy Criteria (Per-Drug Blocks)

    inv-175: Initial therapy — top-level node

    Initial authorization conditions: Member has an FDA‑approved indication for Actimmune AND documentation of diagnosis of chronic granulomatous disease or severe malignant osteopetrosis. Authorize for Plan Year.

    inv-176: Alecensa initial therapy criteria

    Alecensa initial: Diagnosis of ALK‑positive NSCLC with documentation that tumors are ALK‑positive; PA requested for an FDA‑approved indication; duration Plan Year.

    chunks 20,21,24,27

    inv-177: Radicava ORS initial therapy criteria

    Radicava ORS initial: Diagnosis of ALS meeting revised El Escorial criteria; PA requested for an FDA‑approved indication; duration Plan Year.

    chunks 30,31,34,37

    inv-178: ALUNBRIG initial therapy requirements

    ALUNBRIG prerequisites: Metastatic ALK‑positive NSCLC; failed/intolerant/contraindication to Alecensa;

    Coverage duration: Plan Year

    inv-179: Testosterone topical/solution initial therapy

    Testosterone prerequisites: Two separate testosterone levels < 300 ng/dL on different dates; at least one symptom (malaise, fatigue, lethargy, muscle loss, depression, decreased libido);serum testosterone < 300 ng/dL

    Coverage duration: Plan Year

    inv-180: Testosterone — Initial Therapy (duplicate block focus)

    Initial testosterone therapy: Two separate testosterone measurements < 300 ng/dL and at least one symptom (malaise, fatigue, lethargy, muscle loss, depression, decreased libido).serum testosterone < 300 ng/dL

    Required Medical Information

    inv-181: Initial therapy (LDL entry)

    LDL initial therapy: See coverage criteria: LDL >500 mg/dL, supporting genetic/family/xanthoma evidence, prior statin trial/intolerance, prior Repatha or Praluent trial.

    inv-182: Initial therapy (AQNEURSA)

    AQNEURSA initial therapy: See AQNEURSA criteria: prior miglustat failure ≥3 months, weight ≥15 kg, genetic/biochemical confirmation, neurologic symptoms, ambulatory, and baseline functional measures within specified ranges.

    inv-183: Adbry initial therapy prerequisites

    Adbry prior therapy requirement

    Adbry prior therapies: Failure of two of the listed therapies: topical corticosteroid; topical calcineurin inhibitor; phototherapy; oral immunomodulator (azathioprine, cyclosporine, mycophenolate); topical PDE‑4 (Eucrisa).

    inv-184: AUGTYRO initial therapy

    AUGTYRO initial therapy: Diagnosis of ROS1‑positive NSCLC or NTRK fusion‑positive tumor AND contraindication/intolerance/failure of Rozlytrek.

    inv-185: AUSTEDO initial therapy

    AUSTEDO initial therapy: Diagnosis of chorea associated with Huntington's disease OR tardive dyskinesia.

    inv-186: Initial therapy — AVMAPKI/FAKZYNJA co-pack indication

    Initial therapy requirements: Diagnosis, prior platinum therapy, ECOG 0‑1, prior Mekinist or rationale.

    inv-187: Balversa initial therapy

    Balversa initial: Confirmed FGFR3 alteration; locally advanced/metastatic urothelial carcinoma; progression after ≥1 prior systemic therapy; coverage duration Plan Year.

    inv-188: Rufinamide initial therapy

    Rufinamide initial: Inadequate seizure control despite ≥1 anti‑epileptic drug; coverage duration Plan Year.

    inv-189: Initial therapy requirements (lupus nephritis/SLE)

    Initial therapy for lupus/SLE: Previous treatment with at least TWO of corticosteroids, antimalarials, or immunosuppressives; will continue concomitant standard treatment with at least ONE of these.

    inv-190: Initial therapy durations — coverage durations provided for initial therapy

    Coverage durations provided for initial therapy

    Polycythemia Vera initial: Initial authorization: 6 months; reauthorization: Plan Year.
    Ph+ CML initial: Coverage duration: Plan Year.

    inv-191: Initial — BRAFTOVI/MEKTOVI

    Initial authorization requirements for Braftovi/Mektovi

    Mutation positive: Documentation of BRAF V600E or V600K mutation‑positive tumor for indicated cancers.
    Combination regimen: Plan to use encorafenib in combination with binimetinib for melanoma/NSCLC or with cetuximab for metastatic colorectal cancer.

    inv-192: Initial — BRUKINSA

    Initial authorization requirements for Brukinsa

    Indication verification: Document diagnosis of MCL, Waldenström macroglobulinemia, relapsed/refractory FL, or CLL/SLL.
    Prior therapy verification: Document prior therapies as specified (e.g., ≥1 prior therapy for MCL; prior anti‑CD20 for MZL; ≥2 prior lines for FL when used with obinutuzumab).

    inv-193: CABLIVI initial therapy

    Initial authorization requirements

    CABLIVI initial: Diagnosis of aTTP AND started inpatient in combination with plasma exchange.

    Required for initial approval

    inv-194: CALQUENCE initial therapy

    Initial therapy coverage conditions

    CALQUENCE initial: Diagnosis of mantle cell lymphoma and at least one prior therapy.

    Coverage duration: Plan Year

    inv-195: CAPRELSA initial therapy

    Initial therapy coverage conditions

    CAPRELSA initial: Diagnosis of symptomatic or progressive medullary thyroid cancer that is unresectable locally advanced or metastatic.

    Coverage duration: Plan Year

    inv-196: Initial therapy PA — prior authorization applies

    Prior authorization applies

    PA for FDA‑approved use: Prior authorization required for use consistent with all FDA‑approved indications.

    Reauthorization and Continuation Requirements

    inv-197: Reauthorization schedule — Reauthorization timing where specified

    Reauthorization timing where specified

    LDL reauthorization: Reauthorization period: Plan Year.

    inv-198: AQNEURSA continuation

    AQNEURSA continuation

    AQNEURSA continuation: Coverage duration: 6 months; reauthorization requires SARA score stability or improvement.

    inv-199: Adbry reauthorization requirement

    Adbry reauthorization requirement

    Adbry reauthorization: For patients <100 kg who achieved clear or almost clear skin, an every‑4‑week dosing regimen must have been tried prior to reauthorization consideration.

    inv-200: Continuation / coverage duration — Coverage duration and reauthorization expectations for initial therapy

    Continuation / coverage duration — Coverage duration and reauthorization expectations for one medication entry

    Coverage duration: 6 months6 months

    Reauthorization requires documentation of no progression per RECIST v1.1

    inv-201: CABLIVI continuation — Reauthorization requirements for continued coverage

    CABLIVI continuation — Reauthorization requirements for continued coverage of CABLIVI

    Reauthorization evidence: Signs of persistent underlying disease (e.g., suppressed ADAMTS13) AND demonstrated positive clinical response (increase in platelet count; reduction in neurologic symptoms; improvement in organ‑damage markers).

    Required for continuation

    Step Therapy Rules and Prior Trial Requirements

    StepRequirement / Notes
    1
    No step therapy requirements specified in this segment (NIA).
    StepRequirement / Notes
    1
    Patient must have failed, been intolerant to, or have a contraindication to Alecensa prior to ALUNBRIG approval.
    StepRequirement / Notes
    1
    Documentation of prior trial(s) on listed antipsychotics (aripiprazole, clozapine, fluoxetine-olanzapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone). For MDD or schizophrenia, previous trial on Rexulti is required where applicable.
    StepRequirement / Notes
    1
    Prior trial of miglustat for at least 3 months with documented lack of improvement in disease progression is required before AQNEURSA.
    StepRequirement / Notes
    1
    Prior trial of a PCSK9 inhibitor (Repatha OR Praluent) is required before coverage for the LDL-related indication.
    StepRequirement / Notes
    1
    For Adbry, failure of two prior therapies is required (examples: topical corticosteroid; topical calcineurin inhibitor; phototherapy; oral immunomodulator such as azathioprine, cyclosporine, or mycophenolate; or topical PDE-4).
    StepRequirement / Notes
    1
    Requires documentation of contraindication, intolerance, or failure of Rozlytrek prior to AUGTYRO authorization.
    StepRequirement / Notes
    1
    Patient must have been treated with Mekinist or provide a documented medical rationale explaining why Mekinist would be inappropriate.
    StepRequirement / Notes
    1
    Documentation of prior therapies and clinical failure as specified for the indication (examples: prior systemic therapy for Balversa; inadequate seizure control despite ≥1 anti-epileptic drug for Rufinamide).
    StepRequirement / Notes
    1
    Prior treatment with at least two therapies from corticosteroids, antimalarials, or immunosuppressives is required for lupus nephritis/SLE before coverage.
    StepRequirement / Notes
    1
    For Bosulif (Ph+ CML), documentation of prior failure or intolerance to imatinib is required before coverage in chronic phase patients.
    StepRequirement / Notes
    1
    Coverage is limited to FDA-approved indications; off-label uses are not covered as indicated in the policy.
    StepRequirement / Notes
    1
    For CABOMETYX indications, documented prior therapy is required as applicable (e.g., prior sorafenib for HCC; prior VEGFR-targeted therapy for differentiated thyroid cancer; prior everolimus or sunitinib for pNET).
    StepRequirement / Notes
    1
    Prior therapy required before coverage (example: CALQUENCE requires the patient to have been treated with at least one prior systemic therapy).
    StepRequirement / Notes
    1
    No step therapy rules indicated in this fragment (Other Criteria: NIA).

    Medication and Clinical Codes, Key Values

    Medications listedNDC
    BENLYSTA 200 MGIML SOLN A-INJMedication listing as presented
    BENLYSTA 200 MGIML SOLN PRSYRMedication listing as presented
    Medications listedNDC
    BESREMIMedication listing as presented
    Medications listedNDC|DrugName
    CALQUENCE 100 MG TABMedication listed
    Medications listedDrugName
    CAPRELSAMedication listed
    inv-53: Serum testosterone — < 300 ng/dL
    ThresholdSerum testosterone < 300 ng/dL (documented on two separate dates)
    Required documentationTwo separate testosterone levels drawn on different dates showing serum testosterone < 300 ng/dL
    Associated symptomsAt least one qualifying symptom: malaise, fatigue, lethargy, muscle loss, depression, or decreased libido
    inv-54: Serum testosterone — < 300 ng/dL (duplicate entry)
    ThresholdSerum testosterone < 300 ng/dL (documented on two separate dates)
    Required documentationTwo separate testosterone levels drawn on different dates showing serum testosterone < 300 ng/dL
    Associated symptomsAt least one qualifying symptom: malaise, fatigue, lethargy, muscle loss, depression, or decreased libido
    inv-55: Untreated fasting LDL cholesterol — > 500 mg/dL
    Threshold (LDL)> 500 mg/dL (untreated, fasting)
    Triglycerides< 300 mg/dL
    Supporting evidenceGenetic confirmation (mutations in both alleles) OR strong family history (both parents total cholesterol >250 mg/dL) OR xanthomas before age 10
    Prior therapy requirementFailed or currently taking at least one high-intensity statin (atorvastatin, rosuvastatin, simvastatin) OR documented statin intolerance
    Prior PCSK9 trialPrevious trial of Repatha OR Praluent required
    inv-56: Triglycerides — < 300 mg/dL
    ThresholdTriglycerides < 300 mg/dL
    ContextRequired alongside untreated fasting LDL >500 mg/dL for the LDL-related indication
    PurposeEnsures triglycerides are not confounding LDL measurement in extreme hypercholesterolemia evaluation
    inv-57: Patient weight for AQNEURSA — ≥ 15 kg
    Weight thresholdPatient weight ≥ 15 kg
    ContextRequired for AQNEURSA (Niemann‑Pick type C) initial eligibility
    DocumentationWeight recorded as part of required medical information prior to authorization
    inv-58: 9-Hole Peg Test (dominant hand) — ≥ 20 and ≤ 150 seconds
    Test range9‑Hole Peg Test (dominant hand) ≥ 20 and ≤ 150 seconds
    UseAcceptable alternative baseline functional measure for AQNEURSA eligibility (SCAFI subtest)
    ContextOne of the functional criteria required in addition to genetic/clinical confirmation
    inv-59: RECIST progression threshold — >= 20% increase in sum of diameters
    Progression definition>= 20% increase in the sum of diameters of target lesions (RECIST v1.1)
    UseDefines disease progression for reauthorization (no progression required) in the specified oncology indication
    Source standardRECIST version 1.1 criteria as cited in required medical information
    inv-60: Prior AED requirement — >= 1 anti-epileptic drug
    Prior therapy threshold>= 1 anti-epileptic drug (AED)
    DefinitionInadequate seizure control despite treatment with at least one AED is required documentation
    PurposeEligibility criterion for Rufinamide and related seizure indications
    inv-61: Prior therapies for lupus — >= 2 therapies from specified classes
    Prior therapies required>= 2 therapies from specified classes (corticosteroids, antimalarials, immunosuppressives)
    ContextRequired prior treatment for lupus nephritis/systemic lupus erythematosus prior to authorization
    ContinuationPatient must continue concomitant standard treatment with at least one of those agents

    Definitions and Diagnostic Criteria

    inv-146: Required diagnosis / Exclusion — chronic granulomatous disease or severe malignant osteopetrosis; hypersensitivity exclusion
    Required diagnosisDocumented diagnosis of chronic granulomatous disease OR severe malignant osteopetrosis
    ExclusionHypersensitivity to Actimmune or E. coli‑derived products is an exclusion to coverage
    Authorization notePrior authorization is required for FDA‑approved indications and diagnosis documentation must be provided
    inv-147: ALK-positive definition — tumor testing confirming ALK rearrangement
    DefinitionALK‑positive tumor: tumor testing confirming anaplastic lymphoma kinase (ALK) gene rearrangement
    UseRequired medical information for ALK‑targeted therapies (e.g., Alecensa)
    DocumentationMolecular/tumor testing results must be provided to confirm ALK rearrangement
    inv-148: Revised El Escorial criteria — ALS diagnostic criteria
    DefinitionRevised El Escorial criteria: diagnostic criteria used to define amyotrophic lateral sclerosis (ALS)
    UseRequired medical information for Radicava ORS authorization
    DocumentationClinical documentation that ALS diagnosis meets the revised El Escorial criteria should be provided
    inv-149: ALK-positive NSCLC — definition
    DefinitionALK‑positive NSCLC: non‑small cell lung cancer with tumors positive for ALK rearrangement
    UseRequired for ALUNBRIG initial authorization (must also show prior failure/intolerance/contraindication to Alecensa)
    DocumentationTumor ALK status must be documented in required medical information
    inv-150: Biochemical hypogonadism — serum testosterone < 300 ng/dL on two dates
    DefinitionBiochemical hypogonadism: serum testosterone < 300 ng/dL confirmed on two separate dates
    UseDefines low testosterone for coverage of testosterone replacement therapy
    DocumentationTwo separate serum testosterone measurements on different dates required
    inv-151: Low serum testosterone — < 300 ng/dL documented twice
    DefinitionLow serum testosterone: serum testosterone < 300 ng/dL documented on two separate dates
    ImplicationMeets the threshold for initial testosterone therapy consideration when symptoms are present
    Required symptom documentationAt least one qualifying symptom must be recorded (malaise, fatigue, lethargy, muscle loss, depression, decreased libido)
    inv-152: Required medical information (LDL entry) — thresholds and genetic evidence
    LDL threshold> 500 mg/dL (untreated, fasting)
    Triglyceride constraintTriglycerides < 300 mg/dL
    Genetic/family evidenceMutations in both alleles OR strong parental hypercholesterolemia OR childhood xanthomas required as supporting evidence
    inv-153: Required medical information (NPC / AQNEURSA) — miglustat trial, weight, genetic confirmation
    Miglustat trialPrior ≥3 months trial of miglustat with documented lack of improvement required
    WeightPatient weight ≥ 15 kg
    Genetic confirmationGenetically confirmed biallelic NPC1 or NPC2 mutations OR supportive biochemical testing (filipin staining or cholestane triol >2x ULN) when only one allele mutated
    inv-154: DIRA definition
    DefinitionDIRA = deficiency of Interleukin‑1 Receptor Antagonist
    UseListed diagnosis qualifying for Arcalyst coverage
    inv-155: ROS1-positive NSCLC definition
    DefinitionROS1‑positive NSCLC: NSCLC with ROS1 gene rearrangement requiring tumor testing confirmation
    UseRequired medical information for AUGTYRO coverage
    inv-156: NTRK gene fusion-positive tumors definition
    DefinitionNTRK gene fusion‑positive tumors: solid tumors with NTRK gene fusions confirmed by testing
    UseRequired for AUGTYRO coverage when applicable
    inv-157: Chorea (Huntington's disease) definition
    DefinitionChorea associated with Huntington's disease
    UseRequired diagnosis for AUSTEDO coverage
    inv-158: Tardive dyskinesia definition
    DefinitionTardive dyskinesia
    UseRequired diagnosis for AUSTEDO coverage
    inv-159: RECIST v1.1 progression definition
    DefinitionRECIST v1.1 progression = ≥20% increase in sum of diameters of target lesions
    UseApplied to reauthorization/no‑progression requirements in oncology entries
    inv-160: ECOG 0-1 definition
    DefinitionECOG 0–1: performance status required for specified oncology indication (fully active to restricted in strenuous activity but ambulatory)
    UseRequired medical information for recurrent low‑grade serous ovarian cancer indication
    inv-161: FGFR3 genetic alteration — definition
    DefinitionFGFR3 genetic alteration: confirmed FGFR3 mutation or alteration by testing
    UseRequired for Balversa coverage in urothelial carcinoma
    inv-162: Inadequate seizure control — definition
    DefinitionInadequate seizure control = persistent seizures despite treatment with at least one anti‑epileptic drug
    UseRequired documentation for Rufinamide and seizure‑related coverage
    inv-163: Inadequate seizure control (duplicate)
    DefinitionInadequate seizure control despite treatment with at least ONE anti‑epileptic drug
    Redundancy noteDuplicate phrasing appears in required medical information for seizure entries
    inv-164: Prior treatment requirement for lupus — two prior therapies
    RequirementPrevious treatment with at least TWO of: corticosteroids, antimalarials, or immunosuppressives
    ContextPrerequisite for lupus nephritis/SLE coverage
    ContinuationPlan to continue concomitant standard treatment with at least one of those agents required
    inv-165: Hydroxyurea failure/intolerance definition (Polycythemia Vera)
    DefinitionHydroxyurea failure/intolerance: inadequate response or intolerance to hydroxyurea
    UseRequired for Polycythemia Vera initial authorization
    inv-166: Ph+ CML disease phase definitions
    DefinitionPh+ CML disease phases: chronic, accelerated, blast phase (Philadelphia chromosome positive)
    UseRequired to document disease phase and prior imatinib failure/intolerance for chronic phase
    inv-167: BRAF V600E or V600K mutation-positive definition
    DefinitionBRAF V600E or V600K mutation‑positive: tumor positive for codon 600 substitutions confirmed by validated molecular testing
    UseRequired for BRAFTOVI/MEKTOVI coverage in specified indications
    inv-168: Prior therapy lines definition — prior systemic treatments
    DefinitionPrior therapy lines: documentation of previous systemic treatments (e.g., ≥1 prior therapy for MCL; prior anti‑CD20 regimen for MZL; ≥2 lines for FL)
    UseRequired for multiple oncology authorizations (BRUKINSA, BRAFTOVI/MEKTOVI)
    inv-169: aTTP definition — acquired thrombotic thrombocytopenic purpura
    DefinitionaTTP = acquired thrombotic thrombocytopenic purpura
    UseDiagnosis required for CABLIVI initial authorization; must be started inpatient with plasma exchange
    inv-170: DTC definition — differentiated thyroid cancer
    DefinitionDTC = differentiated thyroid cancer (progression after VEGFR therapy; radioactive iodine‑refractory/ineligible)
    UseRequired for CABOMETYX indication documentation
    inv-171: Prior therapy for CALQUENCE — at least one prior systemic therapy
    RequirementAt least one prior systemic therapy required for mantle cell lymphoma (CALQUENCE)
    UseRequired medical information for CALQUENCE initial authorization
    inv-172: Unresectable locally advanced or metastatic medullary thyroid cancer definition
    DefinitionUnresectable locally advanced or metastatic medullary thyroid cancer
    UseRequired diagnosis for CAPRELSA coverage
    inv-173: N-acetylglutamate synthase deficiency definition
    DefinitionN‑acetylglutamate synthase deficiency = cause of hyperammonemia requiring carglumic acid
    UseRequired medical information for carglumic acid authorization
    inv-174: BH4-responsive phenylketonuria definition
    DefinitionBH4‑responsive phenylketonuria = hyperphenylalaninemia responsive to tetrahydrobiopterin (BH4)
    UseRequired medical information for sapropterin authorization

    Site of Care Requirements

    Note

    CABLIVI initial administration must be inpatient with plasma exchange

    The initial administration/start of CABLIVI must occur inpatient in combination with plasma exchange (hospital outpatient site‑of‑care rule).

    Background and Scope

    Actimmune (interferon gamma‑1b) is indicated for specific rare disorders and coverage requires documentation of an FDA‑approved indication. The policy requires a documented diagnosis of either chronic granulomatous disease or severe malignant osteopetrosis and authorizes coverage for the Plan Year. See exclusion criteria for hypersensitivity to Actimmune or E. coli–derived products.